Stannsoporfin

Drug Profile

Stannsoporfin

Alternative Names: Sn-mesoporphyrin; Stanate; tin-mesoporphyrin; Torcan

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Rockefeller University
  • Developer InfaCare Pharmaceutical Corporation; National Hospital of Pediatrics
  • Class Antirheumatics; Heavy metals; Hepatoprotectants; Mesoporphyrins
  • Mechanism of Action Decyclizing heme oxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperbilirubinaemia

Most Recent Events

  • 12 Dec 2016 InfaCare Pharmaceuticals completes an expanded-access programme for Hyperbilirubinemia in USA (NCT00076960)
  • 24 Mar 2016 InfaCare completes the JASMINE_204 phase II trial in Hyperbilirubinaemia (in neonates) in USA (NCT01887327)
  • 26 Jan 2015 Stannsoporfin is still in phase II trials for Hyperbilirubinaemia (In neonates) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top